Enterprise Value

75.91B

Cash

8.928B

Avg Qtr Burn

N/A

Short % of Float

1.35%

Insider Ownership

2.54%

Institutional Own.

89.45%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Evkeeza (evinacumab) Details
Homozygous familial hypercholesterolemia

Approved

Update

EYLEA (aflibercept) Details
Retinopathy of prematurity

Approved

Quarterly sales

EYLEA (aflibercept) Details
Diabetic retinopathy

Approved

Quarterly sales

EYLEA HD (aflibercept) Details
Wet age-related macular degeneration , Diabetic macular edema

Approved

Quarterly sales

Libtayo® (cemiplimab) Details
Non-small cell lung carcinoma, Cutaneous squamous cell carcinoma

Approved

Quarterly sales

Kevzara (sarilumab) Details
Polymyalgia rheumatica

Approved

Quarterly sales

Veopoz™ (pozelimab-bbfg) Details
Rare diseases, CD55-deficient protein-losing enteropathy , CHAPLE disease

Approved

Quarterly sales

Odronextamab Details
Follicular lymphoma, Diffuse large B cell lymphoma

PDUFA

Approval decision

PDUFA

Approval decision

Dupixent Details
Chronic obstructive pulmonary disease

BLA

Submission

Dupixent (dupilumab) Details
Skin disease/disorder, Atopic dermatitis

Phase 3

Data readout

Itepekimab Details
Chronic obstructive pulmonary disease

Phase 3

Data readout

Phase 3

Data readout

Fianlimab + Libtayo® (cemiplimab) Details
Melanoma, Advanced malignancies

Phase 3

Update

Linvoseltamab(BCMAXCD3) Details
Blood cancer, Cancer, Multiple myeloma

Phase 2

Data readout

Dupixent Details
Chronic inducible urticaria

Failed

Discontinued